Johns Hopkins is getting involved with the vast and swiftly growing field psychedelic research.
The prestigious university is throwing down $17 million from a group private donors on its Center for Psychedelic and Consciousness Research. It’s the first its kind the United States and the largest in the world — intended to expand our knowledge and our minds through psychedelic research.
Hopkins Medicine will explore use psilocybin to treat diseases such as opioid addiction, Alzheimer’s disease, eating disorders, depression and chronic Lyme disease.
The most exciting is the potential that a psychedelic treatment model may have, particularly when treating clinical conditions for which we don’t have effective treatments. — Charles Grob, Pressor Psychiatry and Pediatrics at UCLA’s David Geffen School Medicine.
Johns Hopkins’ newfound Center not only sets expectations high for psychedelic insights and advancements, it validates the importance this type research.
When centers like Hopkins attract this money, it’s a validation the field as being legitimate. — Charles Nichols, a pressor in the Department Pharmacology and Experimental Therapeutics at LSU Health Medical Center